Missouri Roundup Lawsuit After the Supreme Court’s FIFRA Preemption Ruling: What 67,000 Cancer Claimants Need to Know Now
If you used Roundup and later heard the words non-Hodgkin’s lymphoma from a doctor — or someone you love did — you are reading this at a specific, frightening moment. The Supreme Court of the United States just ruled 7-2 that the company that made Roundup is not legally liable for failing to warn you about cancer risks on its label. Your phone is probably already buzzing with conflicting information: someone saying the case is over, someone else saying there is still money, a settlement flyer in the mail with a number that looks far smaller than what you heard people were getting. You need straight answers, and you need them from someone who has spent a career in this fight, not someone reading a press release.
We are Attorney911 — The Manginello Law Firm, PLLC. We handle toxic tort and catastrophic injury cases, and we are writing to you as the senior trial team that would evaluate a case exactly like yours. We are not counsel in the Supreme Court case you just read about. We have not been retained by its parties. What we are is a firm that has spent over two decades in courtrooms — including federal court — and we know what a ruling like this does to real people’s claims, and just as importantly, what it does not do. Because here is the first thing you need to hear: the Supreme Court closed one door. It did not close every door. And the settlement fund — $7 billion, with preliminary approval — is still open. But the window to act is narrower than it was yesterday, and the evidence that proves your case is quietly disappearing on a clock that does not care about the Supreme Court.
The Supreme Court’s 7-2 Ruling: What Actually Happened
On June 25, 2026, the Supreme Court ruled in a 7-2 decision that the Federal Insecticide, Fungicide, and Rodenticide Act — known as FIFRA — preempts state-law failure-to-warn claims against Monsanto, now owned by Bayer, in Roundup cancer cases. The case came from Missouri, where a man named John Durnell had sued Monsanto in state court, arguing that under Missouri law the company should have placed a cancer warning on Roundup’s label. The Missouri state court agreed and awarded him more than $1 million in damages. Monsanto — now Bayer — appealed all the way to the Supreme Court, arguing that federal law should override state law on what pesticide labels must say.
The Supreme Court agreed with Bayer. The majority held that because the Environmental Protection Agency has determined glyphosate — the active ingredient in Roundup — is “unlikely to be a human carcinogen” and does not require a cancer warning on glyphosate product labels, FIFRA’s preemption provision bars states from imposing labeling requirements that differ from or exceed federal requirements. In plain English: if the federal regulator said the label does not need a cancer warning, a state court cannot say the company was legally required to put one there.
The two justices who disagreed — Neil Gorsuch and Ketanji Brown Jackson — wrote a dissent that called the majority’s decision “remarkable and regrettable” and said it “unjustifiably closes the courthouse doors” to people like the Missouri plaintiff and others suing Bayer. Justice Jackson wrote that the majority “misunderstands FIFRA’s requirements, misinterprets the scope of FIFRA’s preemption, and ultimately leaves Durnell without a remedy for the significant harms he has suffered.” That dissent matters — not because it changes the law today, but because it maps the legal terrain that future cases may fight on.
The practical effect was immediate. Bayer’s shares jumped more than 16% the morning the ruling came down. And the ruling applies nationwide — not just in Missouri. It overrides the law of every state that would have allowed a failure-to-warn claim based on a missing cancer warning on a pesticide label that the EPA approved without one.
What This Ruling Means for Your Roundup Case — Directly
Can I still sue Bayer/Monsanto for my non-Hodgkin’s lymphoma? The honest answer is: the primary road — the state-law failure-to-warn claim that produced seven-figure verdicts in prior trials — is now preempted nationwide. That specific legal theory, which argued the company should have put a cancer warning on the label and did not, is foreclosed. The Missouri plaintiff’s $1 million+ award has been overturned.
But the case is not necessarily over. Several things remain:
First, the proposed $7 billion settlement fund — which received preliminary approval — is still available and is specifically designed to compensate qualifying claimants who used Roundup and developed non-Hodgkin’s lymphoma. That fund does not depend on the failure-to-warn theory surviving the Supreme Court. It was structured to resolve pending and future litigation regardless of how the Supreme Court ruled. The reported compensation range is approximately $10,000 to $165,000 per qualifying claimant — far less than the seven-figure verdicts some early Roundup plaintiffs received through litigation, but real money that you may be entitled to if you qualify.
Second, alternative legal theories that do not require a label change may still survive. The Supreme Court ruling specifically addressed failure-to-warn through labeling — the argument that the company should have put a cancer warning on the product’s label. The ruling’s scope regarding other product liability theories — design defect, negligent testing or research, fraud and misrepresentation — remains an open question that lower courts will now need to resolve. Claims premised on the product’s inherent design rather than its label, or on affirmative misrepresentations to regulators rather than omissions on the label, may not trigger FIFRA’s labeling-specific preemption provision.
Third, if you are already enrolled in the settlement or have a case pending, your position depends on which theory your case was built on and where it stands in the process. A case built solely on failure-to-warn through labeling is in serious jeopardy. A case built on multiple theories, or one already enrolled in the settlement fund, may have a different path.
The EPA vs. WHO Split: Why Two Scientific Bodies Disagree About Your Cancer
The Supreme Court’s ruling turns on a scientific disagreement that most people have never heard of — and it is the disagreement that may determine whether anyone ever pays for what happened to you.
The EPA has determined that glyphosate is “unlikely to be a human carcinogen.” That finding is what made the Supreme Court’s preemption ruling possible: because the EPA did not require a cancer warning on Roundup labels, FIFRA bars states from demanding one. The EPA’s position is that the scientific evidence does not support classifying glyphosate as a cancer-causing substance.
But a World Health Organization working group — specifically the International Agency for Research on Cancer, IARC — classified glyphosate as “probably carcinogenic” to humans. That is a different conclusion from a different body using a different methodology. The IARC classification looks at whether a substance can cause cancer at any level of exposure — a hazard identification. The EPA’s assessment looks at whether real-world exposure levels are likely to cause harm — a risk assessment. These are not contradictory conclusions; they are different questions. But the Supreme Court treated the EPA’s “no warning required” determination as the controlling federal standard, and that standard is what now preempts state-law warning claims.
This split matters for your case in two ways. First, it means the scientific debate about whether glyphosate causes cancer is not resolved — it is contested at the highest levels of international and federal science. Second, the dissenting justices specifically flagged the majority’s handling of this regulatory framework as a misreading of FIFRA’s scope — which suggests the preemption ruling may be challenged in future cases or by future EPA determinations. If the EPA ever reverses course and requires a cancer warning on glyphosate labels, the preemption landscape changes entirely.
Who Is Bayer/Monsanto: The Defendant’s Corporate Structure
When you sue “Monsanto” for Roundup, you are suing a company that no longer exists under that name. Bayer AG — the German pharmaceutical and agricultural giant — acquired Monsanto in 2018 for approximately $63 billion and assumed its litigation liabilities. Bayer then retired the Monsanto name entirely. But in court filings, the caption defendant is still “Monsanto Company” — the entity that manufactured and sold Roundup for decades, from its debut in 1974 through the acquisition.
This corporate structure matters for your case in several ways. Monsanto is now a wholly-owned subsidiary of Bayer AG. That means the deep pocket — the global parent with pharmaceutical, agricultural, and consumer health operations — is Bayer. The entity that designed, tested, marketed, and sold Roundup for decades is Monsanto. When the Supreme Court ruled “Monsanto is not legally liable” on the failure-to-warn theory, it ruled that the manufacturer of the product is shielded from that specific claim — but the corporate parent, Bayer, remains the entity behind the $7 billion settlement fund and the entity whose shares jumped 16% when the ruling came down.
Bayer has also removed glyphosate from the version of Roundup now sold to residential consumers — though the company maintains the herbicide is safe and was removed only because of litigation risk, not because of any admission of harm. The agricultural and commercial formulations still contain glyphosate. This means the exposure that caused your cancer may have come from a product that has since been reformulated for home use — but the liability for the years you used the original formulation still attaches to the corporate entity that made and sold it.
The $7 Billion Settlement Fund: What You Can Still Recover
The most immediate path to compensation for most Roundup cancer claimants is the proposed $7 billion settlement fund, which has received preliminary approval. Here is what we know about it from public reporting:
The fund is designed to resolve both pending and future Roundup litigation. According to the Associated Press, potential amounts awarded through the settlement could range from approximately $10,000 to $165,000 per qualifying claimant. That is a dramatic compression from the seven-figure and multi-million-dollar verdicts that some early Roundup plaintiffs received through litigation before the Supreme Court ruling.
What this means in dollars: If you used Roundup and were diagnosed with non-Hodgkin’s lymphoma, you may qualify for the settlement fund. The amount you receive will depend on the fund’s qualification criteria and tier classifications — which weigh factors like the duration and frequency of your Roundup exposure, the type and severity of your cancer, your age at diagnosis, and your medical treatment history. A claimant with heavy occupational exposure and an aggressive lymphoma subtype may receive more than a claimant with light residential exposure and a more indolent form.
What you give up: Settlement fund participation almost certainly requires releasing your claims against Bayer/Monsanto. Punitive damages — the punishment awards that were a significant component of prior Roundup verdicts — are unlikely to be available through the settlement fund. And the settlement amount will be a fraction of what a successful litigation outcome might have produced before the Supreme Court ruling.
What you risk by waiting: The settlement has an enrollment window. If you miss it, you may be left with a preempted failure-to-warn claim and no settlement fund to fall back on — the worst of both outcomes. The preliminary approval has been granted; the enrollment deadlines are running. This is not a future possibility. It is happening now.
We want to be honest with you about what these numbers mean. If you were expecting the kind of verdict that made headlines in earlier Roundup trials — figures in the tens of millions — the Supreme Court ruling and this settlement fund represent a fundamental change in what this case is worth. The traditional litigation door has narrowed dramatically. The settlement door is open but pays less. That is the reality, and you deserve to hear it from someone who will not inflate your expectations to get your signature.
Non-Hodgkin’s Lymphoma: The Injury and What It Costs
Non-Hodgkin’s lymphoma is a cancer of the lymphatic system — specifically of the lymphocytes, the white blood cells that are part of your immune system. It is not a single disease but a group of more than 70 subtypes that vary in aggressiveness, treatment, and prognosis. What unites them is that they begin in the lymph system and can spread to virtually any organ.
The treatment is serious and prolonged. For many B-cell non-Hodgkin’s lymphomas — the most common type — the standard first-line treatment is a combination regimen called R-CHOP: rituximab (a monoclonal antibody that targets CD20 on B-cells), cyclophosphamide, doxorubicin, vincristine, and prednisone. This is multi-agent chemotherapy given in cycles over several months. Some patients also receive radiation therapy, particularly for localized disease. For relapsed or refractory cases, treatment may escalate to stem cell transplantation — either autologous (using the patient’s own stem cells) or allogeneic (using a donor’s) — or to newer immunotherapy approaches like CAR-T cell therapy.
The costs are substantial. A full course of R-CHOP, including the rituximab infusions, runs into tens of thousands of dollars per cycle. A stem cell transplant — if the cancer returns — can cost hundreds of thousands. Beyond the medical bills, there is the lost income during treatment and recovery, the long-term side effects (doxorubicin can cause heart damage; vincristine causes nerve damage that may not fully recover), the ongoing surveillance scans and blood work for years after remission, and the psychological toll of living with a cancer that can return.
This is what was taken from the people who used Roundup. The Missouri state court understood this — it awarded the plaintiff more than $1 million. The Supreme Court’s ruling does not change the medical reality. It changes who pays for it.
The Evidence Clock: What Disappears and How Fast
The Supreme Court ruling did not change the clock on your evidence. The proof of your case — whether for the settlement fund or for any surviving litigation theory — is perishable, and some of it is disappearing right now.
Medical records. Your non-Hodgkin’s lymphoma diagnosis is permanent — but the complete treatment record, including pathology reports, staging scans, chemotherapy administration records, and follow-up notes, exists in your providers’ files. Hospitals and oncology clinics operate on record-retention schedules, and historical treatment records can be purged in routine retention cycles. Request your complete medical file — every page, every scan, every pathology report — within weeks, not months. The diagnosis is permanent; the paper trail is not.
Roundup purchase and usage documentation. This is the evidence that proves your exposure, and it is the fastest-decaying proof in your case. Thermal receipt paper — the kind most retail stores use — fades within months. If you bought Roundup at a hardware store or garden center and kept the receipt, that receipt may already be unreadable. Product containers with their labels may have been discarded. Usage logs — if you kept any — may be incomplete. Witness corroboration of how often and how much you used matters, and witness memories fade with every month that passes. Document your Roundup use history now: when, where, how often, what concentration, what formulation, for how many years.
Occupational and residential exposure history. If you used Roundup at work — as a farmer, landscaper, groundskeeper, grounds maintenance worker, or in any agricultural capacity — your exposure was likely heavier and more documented than a residential user. Employment records, pesticide application logs, and co-worker testimony can establish the frequency, duration, and concentration of your glyphosate contact. If your exposure was residential — treating your own lawn, garden, or property — the proof is more personal: your own testimony, family members who saw you use it, neighbors, before-and-after photographs of your property. Obtain detailed sworn statements from corroborating witnesses within months while recall is fresh.
Monsanto/Bayer internal corporate documents. Substantial document production already exists from prior Roundup MDL proceedings and public records. These documents — covering glyphosate safety research, regulatory submissions, alleged ghostwriting of scientific papers, and scientific influence campaigns — may support non-preempted theories like design defect, negligence independent of labeling, or fraud. Much of this material is already accessible through the MDL document depository and public court filings. These records are lower urgency because they are largely already in the public record, but they are high value for any alternative litigation theory.
The Insurance and Corporate Playbook: What Bayer’s Lawyers Will Do
Bayer’s legal strategy was not a secret — the company publicly suggested that a Supreme Court ruling in its favor would help shield it from other lawsuits. Now that the ruling has come down, here is what the defense playbook looks like, and how each play is countered.
Play 1: “The Supreme Court said we are not liable.” Bayer’s lawyers will cite the 7-2 ruling as a blanket shield, arguing that all Roundup claims are now barred. The counter: the ruling specifically addressed failure-to-warn through labeling under FIFRA. It did not address design defect claims, negligence theories independent of labeling, or fraud-based claims. The ruling’s scope will be litigated in lower courts, and a general assertion of “we are not liable for anything” overreads the holding. The dissent itself flagged the majority’s preemption scope as potentially overbroad — which is exactly the argument future plaintiffs will make against extending the ruling beyond labeling.
Play 2: “Take the settlement or get nothing.” Bayer will use the ruling to push claimants into the $7 billion settlement fund at the lower end of the compensation range — $10,000 rather than $165,000 — arguing that the preempted failure-to-warn theory makes the case worthless. The counter: the settlement fund’s own tier classifications are supposed to be based on exposure severity and injury characteristics, not on the legal theory that was preempted. A claimant with heavy occupational exposure and a serious lymphoma subtype should qualify for a higher tier regardless of what the Supreme Court did to the failure-to-warn theory. The settlement enrollment also has qualification criteria that must be met with documentation — and the quality of that documentation is what drives the tier, not the preemption ruling.
Play 3: “The science does not support causation.” Bayer will lean on the EPA’s “unlikely to be a human carcinogen” finding to argue that glyphosate does not cause non-Hodgkin’s lymphoma at all. The counter: the WHO’s IARC classified glyphosate as “probably carcinogenic” — a finding by an internationally recognized cancer research body. The scientific debate is genuine and unresolved. Expert witnesses in epidemiology, medical oncology, and industrial hygiene remain essential for any litigation path, and forensic toxicologists can strengthen specific causation through dose reconstruction — estimating how much glyphosate you were actually exposed to based on your usage history.
Play 4: Delay until enrollment deadlines close. The most insidious play is simple delay — letting individual claimants believe they have time while the settlement enrollment window ticks down. The counter is urgency: the enrollment deadlines are real, and missing them may leave you with a preempted claim and no settlement recovery. The day you call a lawyer is the day the settlement enrollment clock starts working for you instead of against you.
How a Roundup Case Is Actually Built Post-Ruling
Here is how a Roundup case is built after the Supreme Court’s FIFRA preemption ruling — the chronological walk from the day you call to resolution.
Week one: preservation and documentation. The first move is to freeze everything. A litigation-hold letter goes out — not to Bayer, but to every entity that holds your proof: your oncologist’s office, the hospital where you were treated, your pharmacy, your former employer if your exposure was occupational. Simultaneously, we begin assembling your complete exposure history: every brand of glyphosate product you used, every year you used it, every property you treated, every job where Roundup was part of the work. Sworn statements from family members and co-workers who can corroborate your usage are taken while memories are fresh.
Weeks two through four: medical documentation and settlement evaluation. Your complete medical record is pulled — pathology reports confirming the non-Hodgkin’s lymphoma diagnosis, staging scans, treatment records, chemotherapy administration logs, follow-up surveillance, and prognosis. This documentation is what the settlement fund’s qualification criteria and tier classifications are built on. We evaluate which tier you qualify for based on your exposure profile and injury severity, and we compare the settlement offer against any viable litigation theory.
Months one through three: theory evaluation and enrollment decision. This is where the Supreme Court ruling changes everything. We rigorously evaluate whether your case has a non-preempted theory — design defect, negligent testing, fraud, or negligent misrepresentation to regulators — that could survive in a Missouri courtroom or any other venue. We monitor how lower courts are interpreting the Supreme Court’s preemption scope, particularly whether the ruling extends beyond labeling to broader product liability theories. For cases with the strongest exposure profiles and clearest causation, we weigh testing non-preempted theories in plaintiff-friendly venues. For most claimants, the settlement fund enrollment is the primary path — and the enrollment must be filed before the deadline closes with documentation that meets the fund’s qualification criteria.
The decision point. Every Roundup claimant now faces a choice the pre-ruling plaintiffs did not: accept a settlement fund payment of $10,000 to $165,000, or pursue a non-preempted litigation theory with uncertain viability and potentially years of litigation. This is not a choice to make alone, and it is not a choice to make with someone who tells you only what you want to hear.
What Missouri Law Still Allows After the Ruling
Missouri has historically been one of the most plaintiff-friendly venues in the country for product liability and mass tort litigation. Its state court system allows broad discovery, its juries have produced significant plaintiff verdicts in pharmaceutical and chemical exposure cases, and Missouri imposes no statutory caps on damages in product liability cases. The state follows comparative fault principles — meaning your own share of fault reduces your recovery but does not automatically bar it.
The Supreme Court’s ruling changes this — but only partially. The nationwide preemption holding means that Missouri’s venue advantages are substantially diminished for Roundup cases premised specifically on failure-to-warn through labeling. You can no longer file in Missouri state court and argue that Monsanto should have put a cancer warning on the label under Missouri law — FIFRA preempts that theory in every state, including Missouri.
But Missouri law may still provide a path for claims that do not require labeling changes. Alternative theories — design defect claims premised on the product’s inherent formulation rather than its label, negligence claims based on independent duties like post-sale duty to warn or negligent misrepresentation to regulators, and fraud-based claims predicated on affirmative misrepresentations rather than omissions on the label — may still be litigated under Missouri law. Their viability post-ruling is uncertain and must be analyzed carefully against the majority opinion’s reasoning, but the ruling’s specific holding addresses labeling preemption, not the full spectrum of product liability doctrine.
The dissenting justices wrote that the majority “misunderstands FIFRA’s requirements, misinterprets the scope of FIFRA’s preemption, and ultimately leaves Durnell without a remedy for the significant harms he has suffered.”
That framing — that the ruling may have gone further than FIFRA’s text requires — is the legal argument that future plaintiffs will use to narrow the ruling’s reach. Whether Missouri courts accept that argument is an open question. But Missouri’s tradition of plaintiff-friendly product liability law, its broad discovery rules, and its lack of damage caps mean that if any state’s courts are inclined to read the preemption ruling narrowly and allow alternative theories to proceed, Missouri is a candidate.
Missouri’s Statute of Limitations: The Clock That Still Runs
The Supreme Court ruling did not stop the statute of limitations clock. Missouri’s statute of limitations for personal injury claims — including toxic tort and product liability claims — runs five years from the date the cause of action accrues. For wrongful death claims, Missouri sets a shorter deadline. These are deadlines that kill cases regardless of their merit — miss them and the court never reaches the question of whether Roundup caused your cancer or whether Bayer should pay.
The critical question in toxic tort cases is when the clock starts. For latent diseases like non-Hodgkin’s lymphoma that may appear years or decades after exposure, the discovery rule generally provides that the cause of action accrues when the plaintiff knew or should have known of the injury and its connection to the exposure — not on the date you last used Roundup. If you were diagnosed with non-Hodgkin’s lymphoma three years ago and only recently learned that Roundup may have caused it, the clock may have started when you learned of the connection, not when you were diagnosed.
But this is not automatic. The discovery rule’s application varies by jurisdiction and is heavily litigated. Some states impose an outer deadline — a statute of repose — that can cut off a claim even before discovery. Missouri’s treatment of the discovery rule in toxic tort cases must be confirmed by an attorney licensed in Missouri for your specific facts. What we can tell you is this: the clock is running, the Supreme Court ruling did not pause it, and every month you wait is a month you cannot get back.
The Gorsuch-Jackson Dissent: Why Two Justices from Opposite Sides of the Court Called This “Remarkable and Regrettable”
The dissent in this case is unusual — and important — because it joined Justice Ketanji Brown Jackson, one of the Court’s most liberal members, with Justice Neil Gorsuch, one of its most conservative. That pairing crossed ideological lines to say something about this ruling that every Roundup claimant should understand.
The dissent argued that the majority misread FIFRA’s preemption provision. FIFRA, the dissent contended, does not bar states from requiring warnings that go beyond federal minimums — it bars states from imposing requirements that are “inconsistent with” federal labeling standards. The distinction matters: “different from” federal labeling (what the majority held) is not the same as “inconsistent with” federal labeling (what the dissent argued FIFRA actually requires). A state-law warning requirement that adds information the EPA chose not to require is not necessarily inconsistent with the EPA’s labeling scheme — it is additional.
The dissent also flagged the human cost: a man who developed cancer, won in state court, and now has his verdict overturned by a federal preemption ruling that the dissent believes misreads the statute. The phrase “unjustifiably closes the courthouse doors” is not a technical legal observation — it is an acknowledgment that real people with real cancer are being told the law gives them no remedy.
Why this matters for you: the dissent maps the legal arguments that will be made in future cases to narrow the ruling’s reach. If a future EPA determination requires a cancer warning on glyphosate labels, the preemption analysis changes. If lower courts read the ruling narrowly — limiting it to labeling-specific failure-to-warn and not extending it to design defect or fraud — the dissent’s reasoning provides the framework. And if Congress amends FIFRA to clarify the scope of its preemption provision, the dissent’s interpretation of what FIFRA actually means becomes the legislative baseline.
None of this helps you today. But it tells you that the law on this subject is not settled in the way a 7-2 ruling might suggest. The fight over what FIFRA preemption means for Roundup claimants is not over — it is entering its next phase.
If Your Loved One Passed Away: Wrongful Death and Survival Claims
If the person who used Roundup has died — whether from non-Hodgkin’s lymphoma or from any cause while carrying the disease — the claim does not necessarily die with them. Wrongful death and survival claims may exist, but the Supreme Court’s preemption ruling affects them too.
Wrongful death claims — brought by surviving family members for the loss of their loved one — are typically channeled through the same settlement framework as living claimants’ claims, rather than litigated independently. The settlement fund’s qualification criteria should address deceased claimants, and families of deceased Roundup users should be advised that the enrollment and documentation requirements apply to them as well. Survival claims — which carry the decedent’s own claim for pain and suffering experienced before death — face the same preemption analysis as living plaintiffs’ claims: the failure-to-warn theory is preempted, and any surviving theory must be one that does not require a labeling change.
The practical urgency is greater for deceased claimants because the evidence of exposure is often harder to gather — the person who knows how much Roundup they used and for how long is gone. Family members must reconstruct the exposure history from receipts, photographs, employment records, and the testimony of people who knew the decedent’s habits. This evidence decays even faster when the primary source is no longer available.
If your family member used Roundup and died of non-Hodgkin’s lymphoma, you need to speak with someone who handles wrongful death claims immediately — both to evaluate the settlement fund option and to determine whether any non-preempted theory survives.
Frequently Asked Questions
Can I still file a Roundup lawsuit after the Supreme Court ruling?
The failure-to-warn theory that produced the largest Roundup verdicts — the argument that Monsanto should have placed a cancer warning on the label — is now preempted nationwide by the Supreme Court’s FIFRA ruling. However, the $7 billion settlement fund with preliminary approval remains available for qualifying claimants, and alternative legal theories that do not require labeling changes (design defect, negligence independent of labeling, fraud) may survive in some jurisdictions. Whether you can still file depends on your state’s statute of limitations, the specific theory your case would be built on, and whether you qualify for the settlement fund. An attorney must evaluate your individual circumstances.
How much can I get from the Roundup settlement?
According to public reporting, the proposed $7 billion settlement fund may provide compensation ranging from approximately $10,000 to $165,000 per qualifying claimant. The actual amount depends on the fund’s tier classification system, which weighs factors including the duration and frequency of your Roundup exposure, the type and severity of your non-Hodgkin’s lymphoma, your medical treatment history, and other criteria. Higher exposure and more serious injury generally qualify for higher tiers. These amounts are significantly lower than the seven-figure verdicts some early Roundup plaintiffs received through litigation before the Supreme Court ruling.
Is it too late to join the Roundup settlement?
The settlement has received preliminary approval, and enrollment deadlines are running. Whether you are still within the enrollment window depends on the specific terms of the settlement agreement and any court-ordered deadlines. Missing the enrollment deadline may leave you with a preempted failure-to-warn claim and no settlement fund to fall back on. If you have not yet enrolled or filed a claim, you should contact an attorney immediately to determine whether the window is still open for you.
Does the Supreme Court ruling mean Roundup does not cause cancer?
No. The Supreme Court ruling was about legal preemption — whether federal pesticide labeling law overrides state law warning requirements — not about whether glyphosate causes cancer. The EPA has determined glyphosate is “unlikely to be a human carcinogen,” but the World Health Organization’s cancer research agency classified it as “probably carcinogenic.” The scientific debate is genuine and unresolved. The Supreme Court did not rule on the science; it ruled on which regulator’s labeling determination controls when federal and state law conflict.
What if I already have a Roundup lawsuit filed?
If your case is already filed and was built on the failure-to-warn theory, it is in serious jeopardy after the Supreme Court ruling. However, your attorney may be able to amend your complaint to add non-preempted theories — design defect, negligence independent of labeling, or fraud — depending on your jurisdiction’s procedural rules and the specific facts of your case. You may also have the option to enroll in the settlement fund instead of continuing litigation. You should speak with your current attorney immediately about how the ruling affects your specific case and what options remain.
I used Roundup for years and have non-Hodgkin’s lymphoma — what should I do right now?
Three things, in this order. First, gather your medical records — pathology reports confirming your NHL diagnosis, staging, treatment history, and current prognosis. Second, document your Roundup exposure — write down every year you used it, where you bought it, how often you applied it, what concentration and formulation you used, and whether your exposure was occupational or residential. Third, call a lawyer who handles toxic tort cases. The settlement enrollment window is running, the statute of limitations clock is running, and the evidence that proves your exposure is fading. Every day you wait is a day you cannot get back.
Will the Supreme Court ruling be overturned?
The ruling is final and binding as issued. However, the legal landscape could change in several ways: a future EPA determination that requires a cancer warning on glyphosate labels would change the preemption analysis; Congress could amend FIFRA to clarify the scope of its preemption provision; and lower courts could read the ruling narrowly, limiting it to labeling-specific failure-to-warn claims and allowing other theories to proceed. The dissenting justices’ reasoning — particularly the argument that the majority misread FIFRA’s “inconsistency” standard — provides the legal framework for future challenges. But none of these paths is immediate or guaranteed.
Does Missouri’s comparative fault rule affect my Roundup case?
Missouri follows comparative fault principles, meaning your own share of fault — if any — reduces your recovery but does not automatically bar it. In a Roundup case, the defense might argue that you assumed the risk by using a chemical product or that you failed to follow label instructions. After the Supreme Court ruling, the failure-to-warn theory that might have countered these arguments is preempted. But Missouri’s comparative fault rule still applies to any surviving theories, and Missouri has no statutory caps on damages in product liability cases — meaning if a non-preempted theory succeeds, the full range of damages remains available without a statutory ceiling.
What if I never used Roundup but used a generic glyphosate product?
The Supreme Court ruling applies to FIFRA-approved pesticide labels generally, not just Roundup. If you used a generic glyphosate product manufactured by a different company, the same preemption analysis would apply to failure-to-warn claims against that manufacturer. However, the $7 billion settlement fund is specific to Bayer/Monsanto Roundup claims — generic glyphosate manufacturers are not part of that settlement. Your case against a generic manufacturer would need to be evaluated separately, and the alternative non-preempted theories would need to be tested against that specific defendant’s conduct.
How long do I have to file a claim in Missouri?
Missouri’s statute of limitations for personal injury claims runs five years from the date the cause of action accrues. For toxic tort cases involving latent diseases like non-Hodgkin’s lymphoma, the discovery rule may provide that the clock starts when you knew or should have known of your injury and its connection to Roundup exposure — not on the date you last used the product. However, the discovery rule’s application is jurisdiction-specific and must be confirmed by an attorney licensed in Missouri for your specific facts. Do not assume you have time — the clock is running regardless of the Supreme Court ruling.
Why Attorney911
We are Attorney911 — The Manginello Law Firm, PLLC. We are a trial firm that takes toxic tort, catastrophic injury, and wrongful death cases. We are based in Houston, Texas, and we take Missouri cases working with local counsel and pro hac vice admission where required. We do not claim an office in Missouri, and we will not pretend to be something we are not. What we are is a firm with 24-plus years of courtroom experience and the resources to evaluate a case like yours with the depth it demands.
Ralph Manginello is our Managing Partner — 27-plus years licensed, admitted in Texas state court and the U.S. District Court for the Southern District of Texas. He was a journalist before he was a lawyer, which means he reads a Supreme Court ruling and tells you what it actually means in plain English, not what a press release says it means. He has spent his career in courtrooms, including federal court, and he hates losing.
Lupe Peña is our associate attorney — a former insurance-defense attorney who spent years inside a national defense firm, in the rooms where adjusters and their software decided how to deny, delay, and devalue claims. He knows how the other side prices a case, how they set reserves, how they pick IME doctors, and how they engineer recorded statements — because he used to do it. Now he sits on your side of the table. Lupe is fluent in Spanish and conducts full client consultations in Spanish without an interpreter.
We handle toxic tort claims and wrongful death cases with the same approach we bring to every case: the evidence gets frozen on day one, the medicine gets documented completely, the corporate defendant’s structure gets mapped, and the case gets built theory by theory — not on hope, but on proof.
We work on contingency. That means we do not get paid unless we win your case — 33.33% before trial, 40% if the case goes to trial. Your first consultation is free, and it is confidential. You will speak with a live person, not an answering service, 24 hours a day, 7 days a week. Call 1-888-ATTY-911 — that is 1-888-288-9911 — or contact us through our website.
Past results depend on the facts of each case and do not guarantee future outcomes. The Supreme Court’s ruling has fundamentally changed the Roundup litigation landscape, and we will tell you honestly what your case is worth in this new environment — not what it would have been worth before the ruling.
Hablamos Español. Lupe Peña conducts full consultations in Spanish, and our bilingual staff serves your family in the language you are most comfortable speaking.
The Supreme Court closed a door. It did not close every door. The settlement fund is still open. The statute of limitations clock is still running. And the evidence that proves what happened to you is still disappearing, every day, on a schedule that does not care about Supreme Court rulings or settlement enrollment deadlines. Call today. The day you call is the day the clock starts working for you instead of against you.